<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="112447">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01658566</url>
  </required_header>
  <id_info>
    <org_study_id>I 110907</org_study_id>
    <secondary_id>NCI-2009-01760</secondary_id>
    <secondary_id>R21CA137635</secondary_id>
    <nct_id>NCT01658566</nct_id>
  </id_info>
  <brief_title>Tamoxifen Citrate in Treating Premenopausal Women With Estrogen Receptor-Positive Breast Cancer</brief_title>
  <official_title>Pilot Study to Analyze a Novel Mechanism Underlying Response to Tamoxifen Therapy in Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roswell Park Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Roswell Park Cancer Institute</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized clinical trial studies tamoxifen citrate in treating premenopausal women
      with estrogen receptor (ER)-positive breast cancer. Estrogen can cause the growth of breast
      cancer cells. Hormone therapy using tamoxifen citrate may fight breast cancer by blocking
      the use of estrogen by the tumor cells
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Investigate the status of ERalpha-p53 interaction in ERalpha-positive, p53-wild type
      breast tumors in untreated patients and examine how tamoxifen (tamoxifen citrate) therapy
      modifies this interaction.

      II. To confirm the wild type status of p53 and analyze the functional status of p53 pathway
      by monitoring expression of selected p53-target genes in tumors in patients who have or have
      not been treated with tamoxifen.

      OUTLINE: Patients are randomized to 1 of 2 treatment arms.

      Arm I: Patients receive standard of care surgical therapy. Patients may undergo standard
      surgery.

      Arm II: Patients receive tamoxifen citrate orally (PO) daily for 4 weeks in the absence of
      disease progression or unacceptable toxicity. Patients may then undergo standard surgery.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2007</start_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Comparisons of ERalpha-p53 interaction (positive or negative) between independent treatment and control groups</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The proportions of patients with positive ChIP assay will be compared with Fisher's Exact Test. Descriptive statistics such as frequencies and relative frequencies will be computed for all categorical variables. Numeric variables will be summarized using simple descriptive statistics such as mean, standard deviation, quartiles, etc. Ninety-five percent confidence intervals will be computed when appropriate.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparisons of mean messenger ribonucleic acid (mRNA) levels, as measured by quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR), across treatment and control groups</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The difference in log fold intensity between treatment and control will be estimated with an independent samples t-confidence interval. Descriptive statistics such as frequencies and relative frequencies will be computed for all categorical variables. Numeric variables will be summarized using simple descriptive statistics such as mean, standard deviation, quartiles, etc. Ninety-five percent confidence intervals will be computed when appropriate.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Estrogen Receptor-positive Breast Cancer</condition>
  <condition>Stage I Breast Cancer</condition>
  <condition>Stage II Breast Cancer</condition>
  <condition>Stage IIIA Breast Cancer</condition>
  <condition>Stage IIIB Breast Cancer</condition>
  <condition>Stage IIIC Breast Cancer</condition>
  <condition>Stage IV Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I (standard of care)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive standard of care surgical therapy. Patients may undergo standard surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (tamoxifen citrate)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive tamoxifen PO daily for 4 weeks in the absence of disease progression or unacceptable toxicity. Patients may then undergo standard surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tamoxifen citrate</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm II (tamoxifen citrate)</arm_group_label>
    <other_name>Nolvadex</other_name>
    <other_name>TAM</other_name>
    <other_name>tamoxifen</other_name>
    <other_name>TMX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>polymerase chain reaction</intervention_name>
    <description>Correlative study</description>
    <arm_group_label>Arm I (standard of care)</arm_group_label>
    <arm_group_label>Arm II (tamoxifen citrate)</arm_group_label>
    <other_name>PCR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative study</description>
    <arm_group_label>Arm I (standard of care)</arm_group_label>
    <arm_group_label>Arm II (tamoxifen citrate)</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>gene expression analysis</intervention_name>
    <description>Correlative study</description>
    <arm_group_label>Arm I (standard of care)</arm_group_label>
    <arm_group_label>Arm II (tamoxifen citrate)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunohistochemistry staining method</intervention_name>
    <description>Correlative study</description>
    <arm_group_label>Arm I (standard of care)</arm_group_label>
    <arm_group_label>Arm II (tamoxifen citrate)</arm_group_label>
    <other_name>immunohistochemistry</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacogenomic studies</intervention_name>
    <description>Correlative study</description>
    <arm_group_label>Arm I (standard of care)</arm_group_label>
    <arm_group_label>Arm II (tamoxifen citrate)</arm_group_label>
    <other_name>Pharmacogenomic Study</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>matrix-assisted laser desorption/ionization time of flight mass spectrometry</intervention_name>
    <description>Correlative study</description>
    <arm_group_label>Arm I (standard of care)</arm_group_label>
    <arm_group_label>Arm II (tamoxifen citrate)</arm_group_label>
    <other_name>MALDI-TOF Mass Spectrometry</other_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>polymorphism analysis</intervention_name>
    <description>Correlative study</description>
    <arm_group_label>Arm I (standard of care)</arm_group_label>
    <arm_group_label>Arm II (tamoxifen citrate)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>therapeutic conventional surgery</intervention_name>
    <description>Correlative study</description>
    <arm_group_label>Arm I (standard of care)</arm_group_label>
    <arm_group_label>Arm II (tamoxifen citrate)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>nucleic acid sequencing</intervention_name>
    <description>Correlative study</description>
    <arm_group_label>Arm I (standard of care)</arm_group_label>
    <arm_group_label>Arm II (tamoxifen citrate)</arm_group_label>
    <other_name>Gene Sequencing</other_name>
    <other_name>Molecular Biology, Nucleic Acid Sequencing</other_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>protein analysis</intervention_name>
    <description>Correlative study</description>
    <arm_group_label>Arm I (standard of care)</arm_group_label>
    <arm_group_label>Arm II (tamoxifen citrate)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient must consent to be in the study and must have signed an approved consent
             form conforming to institutional guidelines

          -  Core biopsy should definitively demonstrate invasive carcinoma

          -  Invasive carcinoma should be ERalpha receptor positive

          -  The tumor should be approximately at least 1 cm, to account for variability in
             imaging and imaging occult disease (physical exam, mammography, ultrasound); we
             recognize that from time to time because of this variation, there might not be enough
             tissue available for analysis after surgical excision but this will allow the
             greatest opportunity to capture as many eligible patients as possible

          -  Patients in whom surgical excision of the tumor is part of standard of care
             management

          -  Eastern Cooperative Oncology Group (ECOG) score of 0 or 1

          -  Negative serum or urine beta-human chorionic gonadotropin (hCG) pregnancy test at
             screening for patients of child-bearing potential (this is routinely done if the
             patient is premenopausal and having surgery)

          -  Consent to participate in Data Bank and BioRepository (DBBR)

        Exclusion Criteria:

          -  Male patients are not eligible for this study

          -  Female patients with inoperable tumors or women with stage 4 disease diagnosed on
             computed tomography (CT), positron emission tomography (PET), PET/CT or bone scan

          -  Patients with diagnosis by fine needle aspiration (FNA) cytology only

          -  Pregnant or lactating women

          -  Prior therapy for breast cancer, including irradiation, chemo-, immuno- and/or
             hormonal therapy

          -  Patients receiving any hormonal therapy, e.g.,ovarian hormonal replacement therapy,
             infertility medications etc., are not eligible

          -  Nonmalignant systemic disease (cardiovascular, renal, hepatic, etc.) that would
             preclude the patient from being subjected to surgical excision

          -  Psychiatric or addictive disorders that would preclude obtaining informed consent

          -  Patients known or suspected to have hypercoagulable syndrome or with history of
             venous or arterial thrombosis, stroke, transient ischemic attack (TIA), or pulmonary
             embolism

          -  Women with non-invasive disease or microinvasion are not eligible

          -  Women undergoing neoadjuvant chemotherapy are not eligible

          -  Women currently on tamoxifen for prevention are not eligible

          -  Patients shall not receive any herbal/alternative therapies such as flaxseed or soy
             products or black cohosh

          -  Patients with a known mutation in p53 (Li Fraumer/ Syndrome)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shicha Kumar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Roswell Park Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Swati Kulkarni, MD</last_name>
      <phone>773-702-2028</phone>
    </contact>
    <investigator>
      <last_name>Swati Kulkarni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roswell Park</last_name>
      <email>ASKRPCI@Roswellpark.org</email>
    </contact>
    <investigator>
      <last_name>Shicah Kumar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 10, 2014</lastchanged_date>
  <firstreceived_date>July 23, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Citric Acid</mesh_term>
    <mesh_term>Tamoxifen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
